More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine ... in clinical trials that could be the booster shot the stock needs to generate a rebound.

Another study found that in late 2021 and 2022, COVID death rates among unvaccinated people were 14 times the rates of those ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

People age 12 and older may be eligible for a COVID-19 booster depending on which vaccine they received originally ... their boosters at the moment. Moderna submitted data to the Food and Drug ...

Scott said he has received his COVID booster and flu shot ... explored how the human body responded to mRNA COVID-19 vaccines ...

Moderna has reported preliminary clinical ... that it is too early to consider widespread use of a second COVID-19 vaccine booster dose in the EU.